FilingSEC EDGAR8-K
Alaunos Therapeutics Receives Nasdaq Delisting Notice
· SEC accepted
StageDelisting Risk
Filing content
The company received a delisting notice from Nasdaq due to stockholders' equity deficiency and plans to request a hearing.
AI summary of the filing. Please also check the source.Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…